上海莱士：人纤维蛋白原获得《药品注册证书》

Core Viewpoint - Shanghai Raas (002252.SZ) announced that its wholly-owned subsidiary, Tonglu Biopharmaceutical Co., Ltd., has recently received a Drug Registration Certificate from the National Medical Products Administration for its product, Human Fibrinogen [1] Company Summary - Tonglu Biopharmaceutical's product, Human Fibrinogen, is derived from healthy human plasma, which is isolated, purified, and treated for virus removal and inactivation before being freeze-dried [1] - The indication for this product is congenital fibrinogen deficiency or reduction [1]